异戊基-丙基-胺 | 78579-58-5

• 分子结构分类: 有机化合物 - 有机氮化合物
• 中文名称: 异戊基-丙基-胺
• 英文名称: isopentyl-propyl-amine
• 英文别名: Isopentyl-propyl-amin；Propyl-isoamyl-amin；Isoamyl-n-propyl-amine；3-methyl-N-propylbutan-1-amine
• CAS: 78579-58-5
• 化学式: C₈H₁₉N
• mdl: MFCD09949842
• 分子量: 129.246
• InChiKey: NCBKRBDUPKCJEH-UHFFFAOYSA-N

物化性质

• 沸点：
  148-190 °C
• 密度：
  0.7564 g/cm3
• 保留指数：
  909

计算性质

• 辛醇/水分配系数(LogP)：
  2.4
• 重原子数：
  9
• 可旋转键数：
  5
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  12
• 氢给体数：
  1
• 氢受体数：
  1

反应信息

• 作为反应物：
  描述：

  异戊基-丙基-胺 在 双氧水 作用下， 生成 isopentyl-methyl-propyl-amine oxide
  参考文献：
  名称：

  Amine Oxides. III. Selective Formation of Olefins from Unsymmetrical Amine Oxides and Quaternary Ammonium Hydroxides¹

  摘要：

  DOI：

  10.1021/ja01574a037
• 作为产物：
  描述：

  isopentylidene-propyl-amine 在 乙醇 、 铂 作用下， 生成 异戊基-丙基-胺
  参考文献：
  名称：

  Long-term comparison between perindopril and nifedipine in normotensive patients with type 1 diabetes and microalbuminuria

  摘要：

  The aim of this study is to compare the efficacy of an angiotensin-converting enzyme inhibitor with a dihydropyridine calcium channel blocker in preventing progression to macroalbuminuria and/or a decline in renal function in normotensive patients with type 1 diabetes and microalbuminuria. Forty-two patients were randomized to treatment with either perindopril, slow-release nifedipine, or placebo. In the first 3 months, drug dosage was titrated to achieve a decrease in diastolic blood pressure of at least 5 mm Hg. Thirty-three patients had a minimum of 24 months' data, and 25 patients were followed up beyond 36 months (mean, 67 +/- 4 months). Patients were studied every 3 months and at the end of the treatment period; those who remained normotensive discontinued therapy and were followed up for an additional 3 months. Baseline geometric mean albumin excretion rates (AERs) were as follows: perindopril, 66 mug/min; nifedipine, 59 mug/min; and placebo, 66 mug/min. During the first 3 years, 7 of the perindopril-treated but none of the placebo or nifedipine-treated patients reverted to normoalbuminuria (P < 0.01). Median AERs at 3 years of treatment in each group were 23 g/min for perindopril, 122 mug/min for nifedipine, and 112 mug/min for placebo patients (P < 0.01). in patients with more than 3 years' follow-up, median AERs decreased by 45% in the first year and then stabilized in the perindopril group, but increased by 17.6% in the nifedipine group and 27.6% in the placebo group (P < 0.03) in the first year, then increased progressively. In these same patients, there was a significant decline in glomerular filtration rate in the nifedipine group (-7.8 +/- 1.8 mL/min/1.73 m(2)/y), but not in the other two groups (perindopril, -1.0 +/- 1.2 mL/min/1.73 m(2)/y; placebo, -1.3 +/- 1.1 mL/min/1.73 m(2)/y; P = 0.004). At the end or the study, cessation of treatment for 3 months was associated with a doubling of AERs in the perindopril-treated group, but no change in the other two groups (P < 0.001). In conclusion, long-term perindopril therapy is more effective than nifedipine or placebo in delaying the progression of diabetic nephropathy and reducing AER to the normoalbuminuric range (<20 mug/min) in normotensive patients with type I diabetes and microalbuminuria. (C) 2000 by the National Kidney Foundation, Inc.

  DOI：

  10.1016/s0272-6386(05)80003-4

文献信息

• 5-Substituted-2-arylpyridines
  申请人：Neurogen Corporation

  公开号：US20030152520A1

  公开（公告）日：2003-08-14

  Novel 5-substituted-2-arylpyridine compounds are provided. Such compounds can act as selective modulators of CRF receptors. The 5-substituted-2-arylpyridine compounds provided herein are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds provided are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.

  提供了一种新型的5-取代-2-芳基吡啶化合物。这种化合物可以作为CRF受体的选择性调节剂。本文提供的5-取代-2-芳基吡啶化合物在治疗许多中枢神经系统和外周疾病方面具有用途，特别是在应对压力、焦虑、抑郁、心血管疾病和饮食障碍方面。还提供了治疗这些疾病的方法以及包装的药物组合物。提供的化合物还可用作CRF受体定位的探针和CRF受体结合测定中的标准。还给出了使用这些化合物进行受体定位研究的方法。
• DIARYLAMINE-CONTAINING COMPOUNDS AND COMPOSITIONS, AND THEIR USE AS MODULATORS OF C-KIT RECEPTORS
  申请人：Molteni Valentina

  公开号：US20090012094A1

  公开（公告）日：2009-01-08

  Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.

  本文介绍了一种包含二芳胺结构特征的化合物。还介绍了制备这种化合物的方法，使用这种化合物调节c-kit受体活性的方法，以及包含这种化合物的制药组合物和药物。本文还介绍了使用这种化合物、制药组合物和药物治疗和/或预防和/或抑制和/或改善与c-kit受体活性相关的病理学和/或症状学疾病或状况的方法。
• Diarylamine-Containing Compounds and Compositions, and their use as Modulators of C-Kit Receptors
  申请人：Molteni Valentina

  公开号：US20070149538A1

  公开（公告）日：2007-06-28

  Described herein are compounds that include a diarylamine structural feature. Also described herein are methods for making such compounds, methods for using such compounds to modulate the activity of c-kit receptors, and pharmaceutical compositions and medicaments comprising such compounds. Also described herein are methods of using such compounds, pharmaceutical compositions and medicaments to treat and/or prevent and/or inhibit and/or ameliorate the pathology and/or symptomology diseases or conditions associated with the activity of c-kit receptors.

  本文描述了包含二芳胺结构特征的化合物。还描述了制备这种化合物的方法，使用这种化合物调节c-kit受体活性的方法，以及包含这种化合物的药物组合物和药物。本文还描述了使用这种化合物、药物组合物和药物治疗和/或预防和/或抑制和/或改善与c-kit受体活性相关的病理学和/或症状学疾病或状况的方法。
• 5-Substituted-2-Arylpyridines
  申请人：Ge Ping

  公开号：US20080107608A1

  公开（公告）日：2008-05-08

  Novel 5-substituted-2-arylpyridine compounds are provided. Such compounds can act as selective modulators of CRP receptors. The 5-substituted-2-arylpyridine compounds provided herein are useful in the treatment of a number of CNS and periphereal disorders, particularly stress, anxiety, depression, cardiovascular disorders, and eating disorders. Methods of treatment of such disorders and well as packaged pharmaceutical compositions are also provided. Compounds provided are also useful as probes for the localization of CRF receptors and as standards in assays for CRF receptor binding. Methods of using the compounds in receptor localization studies are given.

  本发明提供了一种新型的5-取代-2-芳基吡啶化合物。这些化合物可以作为选择性调节CRP受体的调节剂。本发明提供的5-取代-2-芳基吡啶化合物在治疗许多中枢神经系统和周围疾病方面具有用途，特别是在应对压力、焦虑、抑郁、心血管疾病和进食障碍方面。本发明还提供了治疗这些疾病的方法以及配制的药物组合物。提供的化合物还可用作CRF受体定位的探针，以及CRF受体结合测定中的标准物质。给出了使用这些化合物进行受体定位研究的方法。
• Ophthalmic Compositions for Treating Ocular Hypertension
  申请人：Doherty James B.

  公开号：US20090062280A1

  公开（公告）日：2009-03-05

  This invention relates to the use of potent potassium channel blockers or a formulation thereof in the treatment of glaucoma and other conditions which leads to elevated intraocular pressure in the eye of a patient. This invention also relates to the use of such compounds to provide a neuroprotective effect to the eye of mammalian species, particularly humans.

  本发明涉及在治疗青光眼和其他导致患者眼内压升高的疾病中使用强效钾通道阻滞剂或其配方。本发明还涉及使用这些化合物在哺乳动物，特别是人类的眼中提供神经保护作用。